Next Article in Journal
The Reliability and Medical Students’ Appreciation of Certainty-Based Marking
Next Article in Special Issue
Trends in the Epidemiology and Outcomes of Pneumocystis Pneumonia among Human Immunodeficiency Virus (HIV) Hospitalizations
Previous Article in Journal
Study on Regional Differences and Convergence of Green Development Efficiency of the Chemical Industry in the Yangtze River Economic Belt Based on Grey Water Footprint
Previous Article in Special Issue
Prevalence of Intimate Partner Violence, Substance Use Disorders and Depression among Incarcerated Women in Lima, Perú
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

High Rates of Sexualized Drug Use or Chemsex among Brazilian Transgender Women and Young Sexual and Gender Minorities

Emilia M. Jalil
Thiago S. Torres
Claudia C. de A. Pereira
Alessandro Farias
Jose D. U. Brito
Marcus Lacerda
Daila A. R. da Silva
Nickols Wallys
Gabriela Ribeiro
Joyce Gomes
Thiffany Odara
Ludymilla Santiago
Sophie Nouveau
Marcos Benedetti
Cristina Pimenta
Brenda Hoagland
Beatriz Grinsztejn
1 and
Valdilea G. Veloso
1,† on behalf of the ImPrEP DCE Study Group
Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro 21040-360, Brazil
Escola Nacional de Saúde Pública Sérgio Arouca ENSP-Fiocruz, Rio de Janeiro 21041-210, Brazil
Centro Estadual Especializado em Diagnóstico, Assistência e Pesquisa (CEDAP), Salvador 40100-010, Brazil
Hospital Dia Asa Sul, Brasília 70351-580, Brazil
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT), Manaus 69040-000, Brazil
Centro de Testagem Aconselhamento (CTA) Santa Marta, Secretaria Municipal de Saúde de Porto Alegre, Porto Alegre 90010-040, Brazil
Departamento de Condições Crônicas e Infecções Sexualmente Transmissíveis, Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasília 70719-040, Brazil
Author to whom correspondence should be addressed.
Membership of the ImPrEP DCE Study Group is provided in the Acknowledgments.
Int. J. Environ. Res. Public Health 2022, 19(3), 1704;
Submission received: 23 December 2021 / Revised: 17 January 2022 / Accepted: 19 January 2022 / Published: 2 February 2022


(1) Background: We aimed to estimate sexualized drug use (SDU) prevalence and its predictors among sexual and gender minorities. (2) Methods: We used an online and on-site survey to enroll sexual/gender minorities people between October–December/2020, and multivariate logistic regression to obtain SDU correlates. (3) Results: We enrolled 3924 individuals (280 transgender women [TGW], 3553 men who have sex with men [MSM], and 91 non-binary), 29.0% currently on pre-exposure prophylaxis (PrEP). SDU prevalence was 28.8% (95% confidence interval [CI] 27.4–30.2). TGW had 2.44-times increased odds (95%CI 1.75–3.39) of engaging in SDU compared to MSM, regardless of PrEP use. PrEP use (aOR 1.19, 95%CI 1.00–1.41), South/Southeast region (aOR 1.26, 95%CI 1.04–1.53), younger age (18–24 years: aOR 1.41, 95%CI 1.10–1.81; 25–35 years: aOR 1.24, 95%CI 1.04–1.53), white race/color (aOR 1.21, 95%CI 1.02–1.42), high income (aOR 1.32, 95%CI 1.05–1.67), binge drinking (aOR 2.66, 95%CI 2.25–3.14), >5 sexual partners (aOR 1.88, 95%CI 1.61–2.21), condomless anal sex (aOR 1.49, 95%CI 1.25–1.79), self-reported sexually transmitted infection (aOR 1.40, 95%CI 1.14–1.71), and higher perceived HIV-risk (aOR 1.37, 95%CI 1.14–1.64) were associated with SDU. (4) Conclusions: TGW had the highest SDU odds. SDU may impact HIV vulnerability among key populations and should be addressed in HIV prevention approaches.

1. Introduction

Sexualized drug use (SDU) is the intentional use of illicit drugs before and/or during sex to sustain, enhance, disinhibit, or facilitate the sexual experience [1]. Often ‘chemsex’, a subset of SDU, refers to the use of methamphetamines, gamma-hydroxybutyric acid/gamma-butyrolactone (GHB/GBL), or mephedrone [2], although these definitions are not consensual. Although SDU rates vary greatly depending on the country/region, population, and definition used, current evidence indicates that SDU is on the rise, particularly in high-income countries [2,3,4,5]. Nevertheless, low- and middle-income countries’ (LMIC) reports suggest an important role of SDU in the HIV epidemic, especially among key populations [6,7,8].
HIV infection disproportionately affects key populations worldwide, including in Latin America [9]. In Brazil, despite a 0.4% stable prevalence in the overall population [10], estimates among gay, bisexual and other men who have sex with men (MSM) and transgender women (TGW) reach 18.4% and 31.2%, respectively [11,12,13]. National data for Brazil point to rising incidences among young MSM aged 18–24 years [14]. One in four Brazilian TGW were already living with HIV by the age of 24 [15]. Pre-exposure prophylaxis (PrEP) is an efficacious biomedical strategy to prevent HIV among individuals at risk, including MSM and TGW [16]. Brazil started PrEP implementation in 2017, and this strategy is currently recommended for key populations engaging in risky sexual behavior [17].
SDU contributes to increasing HIV risk as it relates to increased risky sexual behaviors, such as condomless anal sex [18]. In addition, SDU is associated with increased rates of sexually transmitted infections (STI) [19,20]. Moreover, SDU is more common among MSM compared to heterosexual cisgender men and women [21,22,23,24,25]. Although SDU could be perceived as a barrier for PrEP use, some data indicate that individuals reporting SDU had increased rates of post-exposure prophylaxis (PEP) and PrEP use [4]. In addition, recent data showed no evidence that SDU interfered with PrEP persistence [26].
There is a dearth of data on SDU among key populations in Latin America. A few Latin-American studies that addressed SDU among MSM reported prevalences ranging from 4–36.6% [6,27]. There is no data on SDU among Latin-American TGW and non-binary individuals. As PrEP has been slowly incorporated as an HIV prevention strategy in Latin America, it is urgent to gather data on SDU within key populations assessing PrEP. To address this gap, we aimed to estimate SDU prevalence and its predictors among sexual and gender minorities in Brazil.

2. Materials and Methods

2.1. Study Design

This was a cross-sectional study using on-site and online strategies to recruit sexual and gender minorities to participate in a discrete choice experiment (DCE) from October to December 2020. Details of the study design are described elsewhere [28]. Briefly, inclusion criteria were (i) being aged 18+ years, (ii) being cisgender MSM, TGW or non-binary, and (iii) self-reporting as HIV-negative. On-site recruitment occurred in five PrEP/HIV services in all country regions: North (Manaus), Northeast (Salvador), Central-west (Brasília), Southeast (Rio de Janeiro) and South (Porto Alegre). Online recruitment occurred through advertisements on geosocial networking (GSN) and apps (Hornet and Grindr) targeting sexual and gender minorities living in any Brazilian city.

2.2. Outcome

SDU or ‘chemsex’ was assessed using the question: “In the last 6 months, have you used any illicit drug before/during sex?”

2.3. Primary Exposure Variable

Individuals were asked about PrEP use as a multiple choice question with possible answers: never, current and past.

2.4. Covariables

We collected sociodemographic characteristics such as gender (cisgender men, TGW, non-binary or gender fluid), country region (North, Northeast, Central-west, Southeast and South), age (collected continuous; presented in median/interquartile range [IQR] and categorized in 18–24, 25–35, >35 years), race/skin color (Asian, Black, Indigenous, Pardo or Mixed-Black and White; due to the low sample size Asian (N = 46) was grouped with White and Indigenous (N = 26) with Pardo [29]), completed schooling (elementary, secondary and post-secondary), family monthly income (low: <USD 400, middle: USD 401–1200, high: >USD 1200) and sexual orientation (gay/homosexual and other).
We asked about substance use (pre-existing list with an additional open answer) in the past 6 months. We report any illicit drug use (yes/no), tobacco use, marijuana use and stimulant drug use (cocaine, crack, ecstasy or other amphetamines, ketamine, meth, GHB, poppers or other inhalants). Binge drinking was evaluated as: “In the last six months, did you drink five or more drinks in a couple of hours?”. A dose was defined as 1 can of beer (300 mL) or 1 glass of wine (120 mL) or 1 shot of distilled alcohol (30 mL of ex. cachaça, vodka, whisky, tequila, mezcal, or pisco) [30].
We also assessed sexual behavior in the previous 6 months by number of sexual partners (collected continuous, provided as median/IQR and dichotomized in ≤5 and >5), condomless anal sex (yes/no), condomless receptive anal sex (yes/no), steady partner (yes/no), and sexually transmitted infection (STI) (yes/no). HIV perceived risk was assessed with the question: “What is your chance of getting HIV in the next year?”, with possible answers: no, low, moderate, high, 100% sure and I don’t want to answer/I don’t know (considered missing for this analysis; N = 175, 4.5%). Due to the low sample size of some categories and following previous studies [29,31], we further dichotomized into: no/low (779 [19.9%] and 2103 [53.6%], respectively) and moderate/high/100% sure (680 [17.3%], 173 [4.4%] and 14 [0.3%], respectively).
Participants answered about PrEP awareness (“Before today, have you ever heard about PrEP?”, yes/no). We defined PrEP eligibility according to the Brazilian Ministry of Health criteria [17]. For those who never used PrEP before, we inquired about willingness to use PrEP (“Would you be willing to use PrEP for HIV prevention?”) with a 5-point Likert scale; PrEP willingness was defined as ‘highly likely’ [32,33]. For those currently on PrEP, we assessed their PrEP modality (daily oral PrEP, event-driven [ED]-PrEP or injectable PrEP [cabotegravir]). For those reporting daily oral PrEP use, we inquired about complete adherence (no missing pills) during the past 30 days and 7 days. Lastly, we asked about PEP use in the past 12 months.

2.5. Statistical Methods

First, we described the study population according to current PrEP use. We also compared the variables by gender (cisgender men, TGW and non-binary) using chi-square or Ranksum tests for these comparisons, and evaluated effect size using Cramer’s V coefficient. We conducted a bivariate analysis to explore the unadjusted association of the outcome (SDU) with the primary exposure factor (current PrEP use) and other variables, such as sociodemographic, sexual behavior and HIV perceived risk. Lastly, we performed logistic regression models to identify factors associated with SDU overall and according to PrEP use; our hypothesis is that these associations may differ among individuals on and off-PrEP, as previously described [4]. To obtain the multivariable model for SDU overall, we used a backward stepwise modeling approach; variables with a bivariate p-value < 0.02 were included in the initial model and subsequently excluded if p-value > 0.05. Gender, geographic region, race/color, completed schooling, and family monthly income were defined as confounders a priori and maintained in the final model regardless of statistical significance. Exclusions occurred by each variable, beginning with the variable with the highest p-value. After each exclusion, we ran a new model before repeating the process. After this process, the final multivariable model included variables that remained significant (p-value ≤ 0.05) and those defined as confounders a priori. Multivariable models according to PrEP use were obtained with the same process but included the same variables retained in the final multivariable model for SDU overall besides those remaining significant. We tested for multicollinearity of variables retained in final multivariable models by using the variance inflation factor (VIF). All analyses were performed using R version 4.0.5 (The R project).

3. Results

3.1. Study Population

We enrolled 3924 sexual and gender minorities people (280 [7.1%] TGW, 3553 [90.5%] MSM, and 91 [2.3%] non-binary), 29.0% of them currently on PrEP (n = 1139). PrEP use did not differ according to gender identity (Table 1). TGW had lower PrEP awareness, lower current PrEP use, and higher PrEP willingness compared to MSM and non-binary participants (Supplementary Table S1). TGW were more frequently recruited onsite (275/280, 98.2% onsite vs. 5/280, 1.8% online compared to MSM (679/3553, 19.1% onsite vs. 2874/3553, 80.9% online). Number of non-binary individuals recruited onsite and online was similar (47/91, 51.6% vs. 44/91, 48.3%).
Individuals off-PrEP were more commonly recruited online (81.5%) than onsite (18.5%). PrEP users were older, had higher schooling, higher prevalence of illicit drug use, including stimulants, higher number of sexual partners, more frequently engaged in condomless anal sex, and more frequently reported STIs compared to individuals off-PrEP. No or low HIV perceived risk was more common among PrEP users than those off-PrEP (88.1% vs. 72.2%). Among participants on PrEP (n = 1139), 92.5% were on daily oral PrEP (1048), 2.9% (33.0) reported ED-PrEP, and 4.6% (52) were on injectable PrEP. Both injectable PrEP and ED-PrEP were more common among non-binary participants (0 = 0.006) (Supplementary Table S1).

3.2. Prevalence of SDU and Associated Factors among Sexual and Gender Minorities

SDU prevalence was 28.8% (95% confidence interval [CI] 27.4–30.2). Table 2 describes the characteristics of the study population stratified by SDU overall and according to PrEP use. The SDU rates were highest among TGW (40.7%, 95%CI 35.0–46.7), followed by non-binary participants (33.0%, 95%CI 23.7–43.7), and MSM (27.8%, 95%CI 26.3–29.3), and did not differ according to recruitment. TGW had 2.44-times increased odds (95%CI 1.75–3.39) of engaging in SDU compared to MSM, regardless of PrEP use (aOR 2.11, 95%CI 1.13–3.92, among TGW on PrEP and aOR 2.54, 95%CI 1.71–3.77 among TGW off-PrEP) (Table 3).
Overall, in addition to TGW identity, PrEP use (aOR 1.19, 95%CI 1.00–1.41), South/Southeast country region (aOR 1.26, 95%CI 1.04–1.53), younger age (aOR 1.41, 95%CI 1.10–1.81 for 18–24 years, and aOR 1.24, 95%CI 1.04–1.53 for 25–35 years), white race/color (aOR 1.21, 95%CI 1.02–1.42), high income (aOR 1.32, 95%CI 1.05–1.67), binge drinking (aOR 2.66, 95%CI 2.25–3.14), more than 5 sexual partners (aOR 1.88, 95%CI 1.61–2.21), condomless anal sex (aOR 1.49, 95%CI 1.25–1.79), self-reported STI (aOR 1.40, 95%CI 1.14–1.71), and higher perceived HIV-risk (aOR 1.37, 95%CI 1.14–1.64) were associated with SDU.
Among PrEP users, in addition to TGW identity, SDU predictors were: South/Southeast country region [aOR 1.64, 95%CI 1.16–2.34), age between 25–35 years (aOR 1.54, 95%CI 1.12–2.13), binge drinking (aOR 2.85, 95%CI 2.12–3.86), >5 sexual partners (aOR 1.93, 95%CI 1.45–2.57) and self-reported STI (aOR 1.53, 95%CI 1.11–2.09). Among participants off-PrEP, in addition to TGW, non-binary (aOR 1.85, 95%CI 1.04–3.21) participants had increased odds of SDU as compared to MSM. Individuals off-PrEP aged 18–24 years (aOR 1.42, 95%CI 1.06–1.89), reporting binge drinking (aOR 2.56, 95%CI 2.10–3.14), >5 sexual partners (aOR 1.86, 95%CI 1.53–2.25), condomless anal sex (aOR 1.63, 95%CI 1.33–2.01) and higher HIV perceived risk (aOR 1.38, 95%CI 1.13–1.70) also had higher odds of SDU.

4. Discussion

Almost a third of the individuals enrolled in this analysis reported SDU, with higher rates for TGW and non-binary individuals. The multivariable analysis observed that irrespective of PrEP use, SDU was more prevalent among TGW, the population most impacted by HIV infection in Brazil [12]. Furthermore, young individuals and those on PrEP had increased odds of SDU. Behavioral variables, such as binge drinking and risky sexual behavior, were independently associated with SDU. To our knowledge, this is the largest Latin-American sample to evaluate SDU in the context of PrEP use and the first to report SDU according to gender identity in Brazil.
Although SDU estimates are difficult to compare due to the heterogeneity between studies and populations [4], our findings are higher than previous reports enrolling MSM from high income [3,4]. In general, SDU prevalences are higher in samples obtained at sexual health clinics [4], such as part of ours. A Canadian study identified that 24% of 2923 people attending a health unit for PrEP reported SDU in the last year [26]. Another Brazilian study that included 1048 participants identified a 36.6% SDU estimate [6]. Previous analyses conducted by our group found strong associations of sexual behavior and SDU among MSM from Rio de Janeiro [6].
In our analysis, TGW had more than 2-times the odds of reporting SDU as compared to MSM. SDU prevalence among TGW in this study was similar to that of another Brazilian study among travestis (a traditional transgender identity in Brazil that predates queer studies. This identity has been associated with sex work in the past. Although highly stigmatized, the expression has gained importance in LGBTQIA+ activism in the country.) (43%) [34]. TGW are a highly marginalized group in Brazil with high levels of structural transphobia, homicides, violence, sex work, barriers to access fundamental human rights, such as health, education and formal jobs [35]. Brazil ranks first in trans homicides worldwide [36]. Moreover, TGW bear a high burden of HIV worldwide with 49-times higher odds of HIV infection compared to other population groups [37]. Brazilian TGW have HIV prevalences as high as 30% [12,13] and extremely high HIV incidence [38]. Data from ImPrEP, an ongoing demonstration study to assess preparedness for the rollout of effective HIV prevention among key populations in Brazil, Peru and Mexico, demonstrated that TGW presented worse outcomes than MSM in the three countries [39]. Finally, the Brazilian National Surveillance System indicates that PrEP discontinuation occurs among 50% of all TGW on PrEP, in contrast to 38% among MSM [40]. SDU has been associated with condomless anal sex among TGW and may contribute to their increased vulnerability to HIV [41,42].
Age was also associated with SDU, with younger groups (18–24 and 25–35 years) showing higher odds of SDU. In contrast, most studies from developed countries reported higher median ages of people engaging on SDU ranging from 32 to 42 years [4]. Gender and sexual minorities youth may be the populational group at highest HIV risk in Brazil. Brazilian National Data showed an increase in HIV infection among cisgender men aged 15–24 years probably due to the impact of the epidemic among young MSM [43]. In addition, HIV prevalence among MSM was higher in a 2016 Brazilian survey compared to 2009 due to a higher percentage of young participants in the most recent study [44]. Individuals aged 18–24 years had a higher risk of HIV seroconversion in the ImPrEP study [45]. Among TGW, a previous study observed that trans youths had higher odds of using substances and engaging in condomless anal sex, and 24.5% of the participants aged 18–24 years were living with HIV [15].
Binge drinking was also associated with SDU. This is in agreement with a previous Brazilian study that showed a strong association between moderate/high risk for alcohol disorders and SDU [6]. As a licit drug, the risks associated with drinking alcohol have been minimized in our society. Nevertheless, alcohol use has been implicated in several sexual risky behaviors [46], some of which have been consistently associated with SDU in our analysis. In addition, we observed that PrEP users had higher odds of SDU, as previously described [4]. This uncovers the multiple and complex layers that put individuals at risk for HIV and need to be addressed to prevent HIV transmission at the population level.
This study has several limitations. First, this was a cross-sectional study, which hinders causal inferences. As such, we cannot affirm that SDU is associated with worse PrEP outcomes for instance, even though its high prevalence among most vulnerable groups, including young people and TGW, is disturbing. In addition, ours is a convenience sample. As such, our results may not be generalizable to all MSM, TGW, and non-binary persons. Nevertheless, as we used complimentary recruitment strategies, we were able to reach a large and diverse population [47]. Our sample sizes according to gender and sexual minorities were very different, which may interfere with the comparison between the groups. Furthermore, SDU prevalence may be underestimated due to social desirability bias both in in-person and web-based interviews. Most PrEP users were recruited on site and responded to face-to-face interviews, which may have interfered with our results. We only assessed family income, which may be influenced by the number of people included in the family. Additionally, we assessed sexual behaviors and drug use as dichotomic variables, with no evaluation of the different levels of drug use. We did not examine whether any of the predictors acted as moderator variables in this analysis. Finally, the study occurred during the COVID-19 pandemic, the study population and their sexual behaviors may be different from the pre-COVID-19 era. Despite these limitations, this is a large study that evaluated SDU, an understudied topic in LMIC, in view of HIV prevention disaggregated by gender and sexual minorities.

5. Conclusions

Although SDU was common among sexual and gender minorities, TGW had the highest SDU odds. SDU may impact HIV vulnerability among key populations, including TGW, and should be addressed in HIV prevention approaches.

Supplementary Materials

The following are available online at, Table S1: PrEP and PEP information according to gender.

Author Contributions

Conceptualization, T.S.T., C.C.d.A.P., B.G. and V.G.V.; Data curation, E.M.J., T.S.T., B.G. and V.G.V.; Formal analysis, T.S.T.; Funding acquisition, V.G.V.; Investigation, E.M.J., T.S.T., C.C.d.A.P., A.F., J.D.U.B., M.L., D.A.R.d.S., N.W., G.R., J.G., T.O., L.S., S.N., C.P., B.H., B.G. and V.G.V.; Methodology, T.S.T. and C.C.d.A.P.; Project administration, T.S.T., M.B., C.P. and V.G.V.; Resources, A.F., J.D.U.B., M.L., D.A.R.d.S., N.W., G.R., J.G., T.O., L.S., S.N., B.H., B.G. and V.G.V.; Software, T.S.T. and C.C.d.A.P.; Supervision, C.C.d.A.P. and C.P.; Validation, T.S.T. and C.C.d.A.P.; Writing—original draft, E.M.J. and T.S.T.; Writing—review and editing, C.C.d.A.P., A.F., J.D.U.B., M.L., D.A.R.d.S., N.W., G.R., J.G., T.O., L.S., S.N., M.B., C.C.d.A.P., B.H., B.G. and V.G.V. All authors have read and agreed to the published version of the manuscript.


This project was made possible thanks to Unitaid’s funding and support. Unitaid accelerates access to innovative health products and lays the foundations for their scale-up by countries and partners. Unitaid is a hosted partnership of WHO. We thank the Brazil Ministry of Health for their support.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz—INI-Fiocruz (CAAE 28416220.2.1001.5262, 18 April 2020), Secretaria da Saúde do Estado da Bahia—SESAB (CAAE 28416220.2.2003.0052, 22 September 2020), Fiocruz Brasília (CAAE 28416220.2.2002.8027, 17 August 2020), Fundação de Medicina Tropical “Doutor Vieira Dourado” (CAAE 28416220.2.2001.0005, 24 July 2020), Secretaria Municipal de Saúde de Porto Alegre–SMSPA (CAAE 28416220.2.2004.5338, 3 August 2020).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to important vulnerabilities of the study population that prevent us from unrestricted disclosure of the data.


We would like to thank all members of the ImPrEP DCE Study Team: INI-Fiocruz: Nickols Wally de Assis Enedino, Gabriela Teixeira Ribeiro, Daniel R. B. Bezerra, Marcelo Alves, Carolina Souza, Laylla Monteiro; CEDAP: Talita Andrade, Monaliza Rebouças, Thiffany Odara; Hospital Dia Asa Sul: Leonor de Lannoy, João Cunha, Ludymilla Santiago, Juscileia Pimenta; FMT-HVD: Mônica Santos, Antônio Barbosa, Joyce Gomes; CTA Santa Marta: Vinícius Casaroto, Sophie Nouveau.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.


  1. Giorgetti, R.; Tagliabracci, A.; Schifano, F.; Zaami, S.; Marinelli, E.; Busardò, F.P. When “Chems” Meet Sex: A Rising Phenomenon Called “ChemSex”. CN 2017, 15, 762–770. [Google Scholar] [CrossRef] [PubMed]
  2. Edmundson, C.; Heinsbroek, E.; Glass, R.; Hope, V.; Mohammed, H.; White, M.; Desai, M. Sexualised drug use in the United Kingdom (UK): A review of the literature. Int. J. Drug Policy 2018, 55, 131–148. [Google Scholar] [CrossRef] [PubMed]
  3. Schmidt, A.J.; Bourne, A.; Weatherburn, P.; Reid, D.; Marcus, U.; Hickson, F. Illicit drug use among gay and bisexual men in 44 cities: Findings from the European MSM Internet Survey (EMIS). Int. J. Drug Policy 2016, 38, 4–12. [Google Scholar] [CrossRef] [PubMed]
  4. Maxwell, S.; Shahmanesh, M.; Gafos, M. Chemsex behaviours among men who have sex with men: A systematic review of the literature. Int. J. Drug Policy 2019, 63, 74–89. [Google Scholar] [CrossRef]
  5. Tomkins, A.; George, R.; Kliner, M. Sexualised drug taking among men who have sex with men: A systematic review. Perspect Public Health 2019, 139, 23–33. [Google Scholar] [CrossRef]
  6. Torres, T.S.; Bastos, L.S.; Kamel, L.; Bezerra, D.R.B.; Fernandes, N.M.; Moreira, R.I.; Garner, A.; Veloso, V.G.; Grinsztejn, B.; De Boni, R.B. Do men who have sex with men who report alcohol and illicit drug use before/during sex (chemsex) present moderate/high risk for substance use disorders? Drug Alcohol Depend. 2020, 209, 107908. [Google Scholar] [CrossRef]
  7. Blair, K.J.; Segura, E.R.; Garner, A.; Lai, J.; Ritterbusch, A.; Leon-Giraldo, S.; Guilamo-Ramos, V.; Lake, J.E.; Clark, J.; Holloway, I.W. PrEP Awareness, Use, Intention to Use, and Information Source Among Geosocial Networking Application Users in Mexico in 2018–2019. AIDS Behav. 2021, 25, 2743–2754. [Google Scholar] [CrossRef]
  8. Fan, X.; Lau, J.T.F.; Cai, Y.; Li, J.; Ma, T.; Gu, J.; Wang, Z. Prevalence and associated factors of sexualized drug use in sex work among transgender women sex workers in China. AIDS Care 2021, 33, 1098–1106. [Google Scholar] [CrossRef]
  9. UNAIDS 2020 Global AIDS Report. 2020. Available online: (accessed on 15 December 2021).
  10. BRAZIL Boletim Epidemiológico HIV/AIDS 2020. 2020. Available online: (accessed on 15 December 2021).
  11. Kerr, L.; Kendall, C.; Guimarães, M.D.C.; Salani Mota, R.; Veras, M.A.; Dourado, I.; Maria de Brito, A.; Merchan-Hamann, E.; Pontes, A.K.; Leal, A.F.; et al. HIV prevalence among men who have sex with men in Brazil: Results of the 2nd national survey using respondent-driven sampling. Medicine 2018, 97, S9–S15. [Google Scholar] [CrossRef]
  12. Grinsztejn, B.; Jalil, E.M.; Monteiro, L.; Velasque, L.; Moreira, R.I.; Garcia, A.C.F.; Castro, C.V.; Krüger, A.; Luz, P.M.; Liu, A.Y.; et al. Unveiling of HIV dynamics among transgender women: A respondent-driven sampling study in Rio de Janeiro, Brazil. Lancet HIV 2017, 4, e169–e176. [Google Scholar] [CrossRef] [Green Version]
  13. Bastos, F.I.; Bastos, L.S.; Coutinho, C.; Toledo, L.; Mota, J.C.; Velasco-de-Castro, C.A.; Sperandei, S.; Brignol, S.; Travassos, T.S.; dos Santos, C.M.; et al. HIV, HCV, HBV, and syphilis among transgender women from Brazil: Assessing different methods to adjust infection rates of a hard-to-reach, sparse population. Medicine 2018, 97, S16–S24. [Google Scholar] [CrossRef] [PubMed]
  14. Guimarães, M.D.C.; Kendall, C.; Magno, L.; Rocha, G.M.; Knauth, D.R.; Leal, A.F.; Dourado, I.; Veras, M.A.; de Brito, A.M.; Kerr, L.R.F.S. Comparing HIV risk-related behaviors between 2 RDS national samples of MSM in Brazil, 2009 and 2016. Medicine 2018, 97, S62–S68. [Google Scholar] [CrossRef] [PubMed]
  15. Wilson, E.C.; Jalil, E.M.; Moreira, R.I.; Velasque, L.; Castro, C.V.; Monteiro, L.; Veloso, V.G.; Grinsztejn, B. High risk and low HIV prevention behaviours in a new generation of young trans women in Brazil. AIDS Care 2020, 33, 997–1001. [Google Scholar] [CrossRef] [PubMed]
  16. Grant, R.M.; Lama, J.R.; Anderson, P.L.; McMahan, V.; Liu, A.Y.; Vargas, L.; Goicochea, P.; Casapía, M.; Guanira-Carranza, J.V.; Ramirez-Cardich, M.E.; et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N. Engl. J. Med. 2010, 363, 2587–2599. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. BraZil. Protocolo Clínico e Diretrizes Terapêuticas para Profilaxia Pré-Exposição (PrEP) de Risco à Infecção pelo HIV. 2017. Available online: (accessed on 15 December 2021).
  18. Kennedy, R.; Murira, J.; Foster, K.; Heinsbroek, E.; Keane, F.; Pal, N.; Chalmers, L.; Sinka, K. Sexualized drug use and specialist service experience among MSM attending urban and rural sexual health clinics in England and Scotland. Int. J. STD AIDS 2021, 32, 1338–1346. [Google Scholar] [CrossRef]
  19. Guerra, F.M.; Salway, T.J.; Beckett, R.; Friedman, L.; Buchan, S.A. Review of sexualized drug use associated with sexually transmitted and blood-borne infections in gay, bisexual and other men who have sex with men. Drug Alcohol Depend. 2020, 216, 108237. [Google Scholar] [CrossRef]
  20. Ottaway, Z.; Finnerty, F.; Amlani, A.; Pinto-Sander, N.; Szanyi, J.; Richardson, D. Men who have sex with men diagnosed with a sexually transmitted infection are significantly more likely to engage in sexualised drug use. Int. J. STD AIDS 2017, 28, 91–93. [Google Scholar] [CrossRef]
  21. Allen, J.L.; Mowbray, O. Sexual orientation, treatment utilization, and barriers for alcohol related problems: Findings from a nationally representative sample. Drug Alcohol Depend. 2016, 161, 323–330. [Google Scholar] [CrossRef]
  22. Boyd, C.J.; Veliz, P.T.; Stephenson, R.; Hughes, T.L.; McCabe, S.E. Severity of Alcohol, Tobacco, and Drug Use Disorders Among Sexual Minority Individuals and Their “Not Sure” Counterparts. LGBT Health 2019, 6, 15–22. [Google Scholar] [CrossRef]
  23. Evans-Polce, R.J.; Veliz, P.T.; Boyd, C.J.; Hughes, T.L.; McCabe, S.E. Associations between sexual orientation discrimination and substance use disorders: Differences by age in US adults. Soc. Psychiatry Psychiatr. Epidemiol. 2020, 55, 101–110. [Google Scholar] [CrossRef]
  24. Kerridge, B.T.; Pickering, R.P.; Saha, T.D.; Ruan, W.J.; Chou, S.P.; Zhang, H.; Jung, J.; Hasin, D.S. Prevalence, sociodemographic correlates and DSM-5 substance use disorders and other psychiatric disorders among sexual minorities in the United States. Drug Alcohol Depend. 2017, 170, 82–92. [Google Scholar] [CrossRef] [PubMed]
  25. McCabe, S.E.; Hughes, T.L.; West, B.T.; Veliz, P.; Boyd, C.J. DSM-5 Alcohol Use Disorder Severity as a Function of Sexual Orientation Discrimination: A National Study. Alcohol. Clin. Exp. Re. 2019, 43, 497–508. [Google Scholar] [CrossRef] [PubMed]
  26. Flores Anato, J.L.; Panagiotoglou, D.; Greenwald, Z.R.; Trottier, C.; Vaziri, M.; Thomas, R.; Maheu-Giroux, M. Chemsex practices and pre-exposure prophylaxis (PrEP) trajectories among individuals consulting for PrEP at a large sexual health clinic in Montréal, Canada (2013-2020). Drug and Alcohol Dependence 2021, 226, 108875. [Google Scholar] [CrossRef] [PubMed]
  27. Torres, T.S.; Konda, K.; Vega-Ramirez, E.H.; Elorreaga Reyes, O.A.; Diaz-Sosa, D.; Hoagland, B.; Diaz, S.; Pimenta, C.; Bennedeti, M.; Lopez-Gatell, H.; et al. Awareness and factors associated with willingness to use Pre-exposure prophylaxis (PrEP) in Brazil, Mexico and Peru: An online survey among men who have sex with men (MSM) (Preprint). JMIR Public Health Surveill. 2019, 5, e13771. [Google Scholar] [CrossRef] [PubMed]
  28. De Aguiar Pereira, C.C.; Torres, T.S.; Luz, P.M.; Hoagland, B.; Farias, A.; Brito, J.D.U.; Guimarães Lacerda, M.V.; da Silva, D.A.R.; Benedetti, M.; Pimenta, M.C.; et al. Preferences for pre-exposure prophylaxis (PrEP) among men who have sex with men and transgender women at risk of HIV infection: A multicentre protocol for a discrete choice experiment in Brazil. BMJ Open 2021, 11, e049011. [Google Scholar] [CrossRef]
  29. Torres, T.S.; Marins, L.M.S.; Veloso, V.G.; Grinsztejn, B.; Luz, P.M. How heterogeneous are MSM from Brazilian cities? An analysis of sexual behavior and perceived risk and a description of trends in awareness and willingness to use pre-exposure prophylaxis. BMC Infect. Dis. 2019, 19, 1067. [Google Scholar] [CrossRef] [Green Version]
  30. National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Council Approves Definition of Binge Drinking. 2004. Available online: (accessed on 20 February 2019).
  31. Luz, P.M.; Torres, T.S.; Almeida-Brasil, C.C.; Marins, L.M.S.; Veloso, V.G.; Grinsztejn, B.; Cox, J.; Moodie, E.E.M. High-Risk Sexual Behavior, Binge Drinking and Use of Stimulants are Key Experiences on the Pathway to High Perceived HIV Risk Among Men Who Have Sex with Men in Brazil. AIDS Behav. 2021, 25, 748–757. [Google Scholar] [CrossRef]
  32. For the PrEP Brasil Study Team; Hoagland, B.; De Boni, R.B.; Moreira, R.I.; Madruga, J.V.; Kallas, E.G.; Goulart, S.P.; Cerqueira, N.; Torres, T.S.; Luz, P.M.; et al. Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men and Transgender Women in Brazil. AIDS Behav. 2017, 21, 1278–1287. [Google Scholar] [CrossRef]
  33. Jalil, E.M.; Grinsztejn, B.; Velasque, L.; Ramos Makkeda, A.; Luz, P.M.; Moreira, R.I.; Kamel, L.; Fernandes, N.M.; Ferreira, A.C.G.; Hoagland, B.; et al. Awareness, Willingness, and PrEP Eligibility Among Transgender Women in Rio de Janeiro, Brazil. JAIDS J. Acquir. Immune Defic. Syndr. 2018, 79, 445–452. [Google Scholar] [CrossRef]
  34. Martins, T.A.; Kerr, L.R.F.S.; Macena, R.H.M.; Mota, R.S.; Carneiro, K.L.; Gondim, R.C.; Kendall, C. “Travestis”, an unexplored population at risk of HIV in a large metropolis of northeast Brazil: A respondent-driven sampling survey. AIDS Care 2013, 25, 606–612. [Google Scholar] [CrossRef]
  35. Benevides, G.B.; Nogueira, S.N.B. Dossiê dos Assassinatos e da Violência Contra Travestis e Transexuais Brasileiras em 2020; Expressão Popular, ANTRA, IBTE: São Paulo, Brazil, 2021; ISBN 9786558910138. [Google Scholar]
  36. TGEU. TMM Update Trans Day of Remembrance 2020. Transrespect versus Transphobia World Wide. GLS Bank, BIC/SWIFT: GENODEM1GLS, IBAN: DE 66 4306 0967 1153 7962 00, subject line: “TvT Project”. 2020. Available online: (accessed on 20 December 2021).
  37. Baral, S.D.; Poteat, T.; Strömdahl, S.; Wirtz, A.L.; Guadamuz, T.E.; Beyrer, C. Worldwide burden of HIV in transgender women: A systematic review and meta-analysis. Lancet Infect. Dis. 2013, 13, 214–222. [Google Scholar] [CrossRef]
  38. Teixeira, S.L.; Jalil, C.M.; Jalil, E.M.; Nazer, S.C.; Silva, S.D.C.C.; Veloso, V.G.; Luz, P.M.; Grinsztejn, B. Evidence of an untamed HIV epidemic among MSM and TGW in Rio de Janeiro, Brazil: A 2018 to 2020 cross-sectional study using recent infection testing. J. Int. AIDS Soc. 2021, 24, e25743. [Google Scholar] [CrossRef] [PubMed]
  39. Veloso, V.G. ImPrEP project overview and selected results. 11th IAS Conference on HIV Science. 2021. Available online: (accessed on 20 December 2021).
  40. Brazil. Painel PrEP 2021. Available online: (accessed on 15 December 2021).
  41. Weissman, A.; Ngak, S.; Srean, C.; Sansothy, N.; Mills, S.; Ferradini, L. HIV Prevalence and Risks Associated with HIV Infection among Transgender Individuals in Cambodia. PLoS ONE 2016, 11, e0152906. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Nemoto, T.; Operario, D.; Keatley, J.; Han, L.; Soma, T. HIV Risk Behaviors Among Male-to-Female Transgender Persons of Color in San Francisco. Am. J. Public Health 2004, 94, 1193–1199. [Google Scholar] [CrossRef]
  43. BRAZIL Boletim Epidemiológico—HIV/AIDS 2018. 2018. Available online: (accessed on 15 December 2021).
  44. Coelho, L.E.; Torres, T.S.; Veloso, V.G.; Grinsztejn, B.; Jalil, E.M.; Wilson, E.C.; McFarland, W. The Prevalence of HIV Among Men Who Have Sex With Men (MSM) and Young MSM in Latin America and the Caribbean: A Systematic Review. AIDS Behav. 2021, 25, 3223–3237. [Google Scholar] [CrossRef]
  45. Caceres, C.F.; Konda, K.A.; Moreira, R.; Leite, I.; Cunha, M.; Hoagland, B.; Guanira, J.V.; Vermandere, H.; Vega, H.; Grinsztejn, B.; et al. Early predictors of seroconversion among enrolees in a PrEP programme in Brazil, Mexico and Peru—The IMPREP Demonstration study. J. Int. AIDS Soc. 2021, 24, 32–34. [Google Scholar]
  46. Fritz, K.; Morojele, N.; Kalichman, S. Alcohol: The forgotten drug in HIV/AIDS. Lancet 2010, 376, 398–400. [Google Scholar] [CrossRef] [Green Version]
  47. Bezerra, D.R.B.; Torres, T.; Coelho, L.; Jalil, C.; Carvalheira, E.; Granjeiro, J.R.; Araujo, T.; Freitas, J.; Cerqueira, C.; Monteiro, L.; et al. Online and venue-based recruitment strategies are complementary to reach high risk MSM for a large PrEP service in Rio de Janeiro, Brazil. 2020. Available online: (accessed on 15 December 2021).
Table 1. Sociodemographic characteristics, substance use, and sexual behavior of the study population according to current PrEP use.
Table 1. Sociodemographic characteristics, substance use, and sexual behavior of the study population according to current PrEP use.
Current PrEP UseCramer’s V Coefficient 3p-Value
N = 2785N = 1139
Gender 0.010.834
Cisgender men2521 (90.5)1032 (90.6)
Transgender women197 (7.1)83 (7.3)
Non binary67 (2.4)24 (2.1)
Recruitment 0.25<0.001
On site516 (18.5)485 (42.6)
Online2269 (81.5)654 (57.4)
Geographic region 0.19<0.001
North55 (2.0)108 (9.5)
Northeast326 (11.7)73 (6.4)
Central-west247 (8.9)78 (6.8)
Southeast1825 (65.5)775 (68)
South332 (11.9)105 (9.2)
Median (IQR)31 (26,37)32 (27,38) 0.001
18–24505 (18.1)165 (14.5)0.0530.004
25–351420 (51.0)574 (50.4)
>35860 (30.9)400 (35.1)
Race/color 0.0060.932
White/Asian1539 (56.0)624 (55.6)
Pardo/Indigenous767 (27.9)313 (27.9)
Black442 (16.1)186 (16.6)
Completed schooling 0.0420.035
Elementary179 (6.5)50 (4.4)
Secondary782 (28.2)341 (30.0)
Post-secondary1812 (65.3)744 (65.6)
Family monthly income 0.0170.566
Low916 (34.2)351 (32.4)
Middle1085 (40.5)453 (41.8)
High679 (25.3)280 (25.8)
Sexual Orientation 0.0310.053
Gay or homosexual2185 (78.5)925 (81.2)
Other600 (21.5)214 (18.8)
Any illicit drug use 11118 (40.1)533 (46.8)0.061<0.001
Tobacco use 1903 (32.4)351 (30.8)0.0160.327
Marijuana use 1884 (31.7)405 (35.6)0.0370.021
Stimulant drug use 1591 (21.2)323 (28.4)0.077<0.001
Binge drinking 11603 (57.6)677 (59.4) 0.279
Number of sexual partners 1
Median (IQR)4 (2,10)7 (3,15) <0.001
≤51828 (65.6)535 (47)0.173<0.001
>5957 (34.4)604 (53.0)0.017
Condomless anal sex 11765 (63.4)923 (81.0)0.173<0.001
Condomless receptive anal sex 11230 (44.2)718 (63.0)0.171<0.001
Steady partner 1960 (34.5)491 (43.1)0.081<0.001
Reported STI 1370 (13.3)265 (23.3)0.123<0.001
HIV perceived risk 2 (N = 3749) 0.171<0.001
No/Low1909 (72.2)973 (88.1)
Moderate/High/100% sure735 (27.8)132 (11.9)
All results are shown as number of respondents in that category followed by percentage in parentheses; 1 Previous 6 months before study visit; 2 In the next year after the study visit; 3 Cramer’s V coefficients indicate small effect size for all evaluated variables.
Table 2. Characteristics of the study population stratified by SDU overall and according to PrEP use.
Table 2. Characteristics of the study population stratified by SDU overall and according to PrEP use.
Overall Sample (N = 3924)Current PrEP Use
No (N = 2785)Yes (N = 1139)
Sexualized drug use (SDU)No
2794 (71.2)
1130 (28.8)
2039 (73.2)
746 (26.8)
755 (66.3)
384 (33.7)
Current PrEP use
No2039 (73.2)746 (26.8)NANANANA
Yes755 (66.3)384 (33.7)NANANANA
Cisgender men2567 (72.2)986 (27.8)1880 (74.6)641 (25.4)687 (66.6)345 (33.4)
Transgender women166 (59.3)114 (40.7)115 (58.4)82 (41.6)51 (61.4)32 (38.6)
Non-binary61 (67)30 (33)44 (65.7)23 (34.3)17 (70.8)7 (29.2)
Geographical region
North/Northeast/Central-west652 (73.5)235 (26.5)459 (73.1)169 (26.9)193 (74.5)66 (25.5)
South/Southeast2142 (70.5)895 (29.5)1580 (73.2)577 (26.8)562 (63.9)318 (36.1)
Age (years)
18–24461 (68.8)209 (31.2)348 (68.9)157 (31.1)113 (68.5)52 (31.5)
25–351386 (69.5)608 (30.5)1028 (72.4)392 (27.6)358 (62.4)216 (37.6)
>35947 (75.2)313 (24.8)663 (77.1)197 (22.9)284 (71.0)116 (29.0)
White/Asian1532 (55.5)631 (56.7)906 (73.1)334 (26.9)356 (69.3)158 (30.7)
Black/Pardo/Indigenous1226 (44.5)482 (43.3)1107 (73.4)401 (26.6)389 (63.9)220 (36.1)
Completed schooling
Elementary152 (66.4)77 (33.6)117 (65.4)62 (34.6)35 (70)15 (30)
Secondary797 (71)326 (29)565 (72.3)217 (27.7)232 (68)109 (32)
Post-secondary1835 (71.8)721 (28.2)1351 (74.6)461 (25.4)484 (65.1)260 (34.9)
Family monthly income
Low900 (71)367 (29)660 (72.1)256 (27.9)240 (68.4)111 (31.6)
Middle1120 (72.8)418 (27.2)812 (74.8)273 (25.2)308 (68)145 (32.0)
High663 (69.1)296 (30.9)489 (72)190 (28)174 (62.1)106 (37.9)
Binge drinking
No1354 (82.4)290 (17.6)990 (83.8)192 (16.2)364 (78.8)98 (21.2)
Yes1440 (63.2)840 (36.8)1049 (65.4)554 (34.6)391 (57.8)286 (42.2)
Number of partners
≤51833 (77.6)530 (22.4)1432 (78.3)396 (21.7)401 (75)134 (25)
>5961 (61.6)600 (38.4)607 (63.4)350 (36.6)354 (58.6)250 (41.4)
Condomless anal sex1
No975 (78.9)261 (21.1)818 (80.2)202 (19.8)157 (72.7)59 (27.3)
Yes1819 (67.7)869 (32.3)1221 (69.2)544 (30.8)598 (64.8)325 (35.2)
No2400 (73.0)889 (27.0)1796 (74.4)619 (25.6)604 (69.1)270 (30.9)
Yes394 (62.0)241 (38.0)243 (65.7)127 (34.3)151 (57)114 (43)
Steady partner
No1769 (71.5)704 (28.5)1342 (73.5)483 (26.5)427 (65.9)221 (34.1)
Yes1025 (70.6)426 (29.4)697 (72.6)263 (27.4)328 (66.8)163 (33.2)
HIV perceived risk
No/Low2096 (72.7)786 (27.3)1452 (76.1)457 (23.9)644 (66.2)329 (33.8)
Moderate/High/100% sure560 (64.6)307 (35.4)476 (64.8)259 (35.2)84 (63.6)48 (36.4)
All results are shown as number of respondents in that category followed by percentage in parentheses; bold: p < 0.05.
Table 3. Factors associated with SDU, overall and stratified by current PrEP use.
Table 3. Factors associated with SDU, overall and stratified by current PrEP use.
Current PrEP Use
All (N = 3924)No (N = 2785)Yes (N = 1139)
OR (95% CI)aOR (95% CI)OR (95%CI)aOR (95% CI)OR (95%CI)aOR (95% CI)
Current PrEP use
Yes1.39 (1.20–1.61) ***1.19 (1.00–1.41) *NANANANA
On site0.99 (0.84–1.16)NANANANANA
Cisgender menRef.Ref.Ref.Ref.Ref.Ref.
Transgender women1.79 (1.39–2.29) ***2.44 (1.75–3.39) ***2.09 (1.55–2.81) ***2.54 (1.71–3.77) ***1.25 (0.78–1.97)2.11 (1.13–3.92) *
Non-binary1.28 (0.81–1.98)1.52 (0.92–2.46)1.53 (0.90–2.53)1.85 (1.04–3.21) *0.82 (0.31–1.92)0.87 (0.30–2.34)
Geographical region
South/Southeast1.16 (0.98–1.37)1.26 (1.04–1.53) *0.99 (0.81–1.21)1.13 (0.90–1.43)1.65 (1.22–2.27) **1.64 (1.16–2.34) **
Age (years)
18–241.37 (1.11–1.69) **1.41 (1.10–1.81) **1.52 (1.19–1.94) ***1.42 (1.06–1.89) *1.12 (0.76–1.66)1.32 (0.82–2.13)
25–351.33 (1.13–1.56) ***1.24 (1.04–1.53) *1.28 (1.05–1.56) *1.13 (0.91–1.41)1.48 (1.12–1.95) **1.54 (1.12–2.13) **
White/Asian1.05 (0.91–1.21)1.21 (1.02–1.42) *0.96 (0.81–1.14)1.21 (0.99–1.48)1.28 (0.99–1.64)1.20 (0.89–1.62)
Completed schooling
Secondary0.81 (0.60–1.10)1.00 (0.69–1.46)0.72 (0.51–1.03)0.99 (0.65–1.52)1.10 (0.58–2.15)1.20 (0.55–2.72)
Post-secondary0.78 (0.58–1.04)1.10 (0.75–1.63)0.64 (0.47–0.90) **1.01 (0.66–1.58)1.25 (0.68–2.40)1.49 (0.66–3.50)
Family monthly income
Middle0.92 (0.78–1.08)1.06 (0.87–1.30)0.87 (0.71–1.06)1.08 (0.85–1.38)1.02 (0.76–1.37)1.01 (0.70–1.47)
High1.09 (0.91–1.31)1.32 (1.05–1.67) *1.00 (0.80–1.25)1.29 (0.98–1.71)1.32 (0.95–1.83)1.42 (0.91–2.21)
Binge drinking
Yes2.72 (2.34–3.18) ***2.66 (2.25–3.14) ***2.72 (2.27–3.28) ***2.56 (2.10–3.14) ***2.72 (2.08–3.57) ***2.85 (2.12–3.86) ***
Number of partners
>52.16 (1.88–2.49) ***1.88 (1.61–2.21) ***2.09 (1.76–2.48) ***1.86 (1.53–2.25) ***2.11 (1.64–2.73) ***1.93 (1.45–2.57) ***
Condomless anal sex
Yes1.78 (1.52–2.09) ***1.49 (1.25–1.79) ***1.80 (1.50–2.17) ***1.63 (1.33–2.01) ***1.45 (1.05–2.02) *1.18 (0.82–1.71
Reported STI
Yes1.65 (1.38–1.97) ***1.40 (1.14–1.71) **1.52 (1.20–1.91) ***1.27 (0.97–1.65)1.69 (1.27–2.24) ***1.53 (1.11–2.09) **
Steady partner
Yes1.04 (0.91–1.20)NANANANANA
HIV perceived risk
Moderate/High/100% sure1.46 (1.24–1.72) ***1.37 (1.14–1.64) **1.73 (1.44–2.08) ***1.38 (1.13–1.70) **1.12 (0.76–1.63)1.35 (0.89–2.05)
OR: odds ratio (bivariate analysis); aOR: adjusted odds ratio (multivariate analysis); CI: confidence interval; * p < 0.01; ** p < 0.001; *** p < 0.0001; no relevant collinearity verified by VIF among variables retained in final multivariate models (VIF < 1.84).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Jalil, E.M.; Torres, T.S.; de A. Pereira, C.C.; Farias, A.; Brito, J.D.U.; Lacerda, M.; da Silva, D.A.R.; Wallys, N.; Ribeiro, G.; Gomes, J.; et al. High Rates of Sexualized Drug Use or Chemsex among Brazilian Transgender Women and Young Sexual and Gender Minorities. Int. J. Environ. Res. Public Health 2022, 19, 1704.

AMA Style

Jalil EM, Torres TS, de A. Pereira CC, Farias A, Brito JDU, Lacerda M, da Silva DAR, Wallys N, Ribeiro G, Gomes J, et al. High Rates of Sexualized Drug Use or Chemsex among Brazilian Transgender Women and Young Sexual and Gender Minorities. International Journal of Environmental Research and Public Health. 2022; 19(3):1704.

Chicago/Turabian Style

Jalil, Emilia M., Thiago S. Torres, Claudia C. de A. Pereira, Alessandro Farias, Jose D. U. Brito, Marcus Lacerda, Daila A. R. da Silva, Nickols Wallys, Gabriela Ribeiro, Joyce Gomes, and et al. 2022. "High Rates of Sexualized Drug Use or Chemsex among Brazilian Transgender Women and Young Sexual and Gender Minorities" International Journal of Environmental Research and Public Health 19, no. 3: 1704.

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop